Management of malignant pleural mesothelioma: have we made any progress?

摘要: As the incidence of malignant pleural mesothelioma (MPM) is increasing in next decades, treatment a challenge. The past 2 years have seen number promising achievements management patients with MPM. Treatment symptomatic effusion through indwelling catheter (IPC) may allow for an individualized treatment. Advances systemic targeted agents will undoubtedly gain by discovery driver mutation which be selectively targeted. In meantime, addition monoclonal antibodies to standard chemotherapy backbone might result modest improvement outcome selected presence ligand. New techniques radiation therapy, intensity-modulated radiotherapy, helical tomography and proton-therapy are exciting advances multimodality enhancing local control therefore improving overall survival. role surgery remains controversial should further explored. Surgical procedures consist extrapleural pneumonectomy or lung sparing operations like debulking parietal visceral pleura (extended) pleurectomy/decortication. Where therapy lead improved disease-free survival survival, type cyto-reductive procedure on institutional surgeon's experience. increase matched only researchers studies. It up clinicians support these efforts stimulating their participate this clinical research.